相关实验视频
Updated: Jan 13, 2026

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
乳酸菌 (Lacticaseibacillus rhamnosus MP108) 对儿童功能性便秘症状和肠道微生物群的影响
Caixia Peng1, Yunfeng Pan2, Minchan Wu1
1Department of Nutrition Science and Food Hygiene, Xiangya School of Public Health, Central South University, Changsha, Hunan, China.
Lacticaseibacillus rhamnosus MP108显著改善了功能性便秘 (FC) 的儿童的临床症状和肠道微生物群多样性. 这种益生菌干预为儿科FC管理提供了一个有希望的新方法.
科学领域:
- 儿科胃肠病学 儿科胃肠病学
- 微生物组研究 微生物组研究
- 临床营养学 临床营养学
背景情况:
- 功能性便秘 (FC) 是一种常见的儿科胃肠道疾病.
- 肠道微生物群失生症与FC的病理生理学有关.
- 对于幼儿FC的特定益生菌菌株的研究有限.
研究的目的:
- 评估Lacticaseibacillus rhamnosus MP108在改善6至36个月龄的儿童中FC的临床症状方面的疗效.
- 评估 Lacticaseibacillus rhamnosus MP108 补充剂对肠道微生物群组成和多样性的影响.
主要方法:
- 一项为期4周的随机,双盲,安慰剂对照试验,涉及154名被诊断患有FC的儿童 (6-36个月).
- 参与者接受了乳糖菌麻虫MP108或马尔托德克斯 (安慰剂).
- 评估了临床结果 (排便频率,便硬度,治疗成功率) 和肠道微生物群组成 (16S rRNA测序).
主要成果:
- 与安慰剂相比,Lacticaseibacillus rhamnosus MP108组的治疗成功率显著更高 (83.1%与63.6%相比).
- 在干预组中观察到改善的每周排便频率和便一致性 (BSFS分数).
- 观察到肠道微生物群的显著变化,包括增加的α多样性和较高的Lacticaseibacillus和Bifidobacteriaceae的相对丰度.
结论:
- 乳酸菌cillus rhamnosus MP108补充剂有效改善幼儿功能性便秘的关键临床症状.
- 益生菌调节肠道微生物群结构,表明其治疗作用的潜在机制.
- 这项研究提供了支持Lacticaseibacillus rhamnosus MP108作为儿科FC的潜在治疗剂的新证据.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
Drugs Affecting GI Tract Motility: Other Laxatives
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Irritable Bowel Syndrome III: Medical and Nursing Management
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

